NEW YORK – Drug distributor, Reckitt Benckiser Group has agreed to pay $700 million over improperly marketing an opioid-addiction treatment.
New York Attorney General Letitia James and Ohio AG Dave Yost announced the settlement Wednesday.
Reckitt reportedly misled the public about the real impacts of suboxone and encouraged physicians to wrongly prescribe it.
False claims were also being submitted to government health care programs.
Suboxone is approved to treat opioid addiction but its active ingredient, buprenorphine, makes its addictive.
Out of the $700 million, over $400 million will go to Medicaid programs.
The civil settlement resolves claims from 2010 through 2014.